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Tolerance to Intravenous Nitroglycerin in Patients With Congestive
Heart Failure: Role of Increased Intravascular Volume, Neurohumoral
Activation and Lack of Prevention With N-Acetylcysteine
JOCELYN DUPUIS, MD, GUY LALONDE, MD, FACC, RAYMOND LEMIEUX, MD,
JEAN L. ROULEAU, MD, FACC
Montreal, Quebec, Canada
To better understand the mechanism of nitrate tolerance in
patients with congestive heart failure, 13 patients received a
24 h infusion of nitroglycerin (l.5 /Lg/kg body weight per
min) with or without N-acetyIcysteine (225 mg/kg per 24 h).
The infusions were separated by a 24 h nitrate-free interval.
By the end of the nitroglycerin infusion, mean arterial
pressure had returned to baseline values and there was a
significant increase in ventricular filling pressures and
systemic vascular resistance compared with values after 1h
of treatment. The simultaneous infusion of N-acetyIcysteine
had no effect on these changes.
Although a strict nuid restriction of 1.5 liters/day was
maintained for 1 week before and throughout the study,
after 24 h of nitroglycerin infusion there was a significant
and similar degree of hemodilution whether nitroglycerin
Nitrates have been used successfully in the treatment of
angina (1,2) and more recently to improve ventricular func-
tion in patients with congestive heart failure (3--6). Unfortu-
nately, when they are given without interruption. a certain
degree of tolerance to their beneficial effects appears within
24 h (1.2.5-10). the most important mechanism by which
nitrate tolerance occurs appears to be a loss of its direct
pharmacologic vasodilating properties (I). One theory ad-
vanced to explain this tolerance is sulfhydryl group depletion
(5-14). More recent studies (\5-17) have questioned this
mechanism and proposed that tolerance is the result of a
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was infused alone (9.1 ± 4.3%) or with N-acetylcysteine
(8.7 ± 4.1%). This hemodilution corresponded to an in-
crease in intravascular volume of 745 ± 382 ml, most of
which occurred during the 1st h. Plasma renin activity
increased and plasma atrial natriuretic peptide decreased
during the infusion.
The results of this study suggest that nitrate tolerance is
multifactorial. In addition to the previously described phar-
macologic tolerance to the effect of nitroglycerin on vascu-
lar smooth muscle, a capillary nuid shift from the extravas-
cular to intravascular space appears to be involved,
especially during the 1st h of the infusion. A third mecha-
nism, renex neurohumoral activation, also seems to con-
tribute to the genesis of nitroglycerin tolerance.
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change in affinity of the intracellular transformation site for
organic nitrates. Two nonpharmacologic causes of nitrate
tolerance have also been proposed: reflex neurohumoral
activation (5,6,18) and intravascular volume expansion
(\9-22).
In this study. we examined I) whether a continuous
infusion of N-acetylcysteine in doses comparable with those
used in the treatment of acetaminophen intoxication could
prevent nitrate tolerance; 2) the relation of changes in
intravascular volume to the development of hemodynamic
tolerance to nitroglycerin; and 3) the role of neurohumoral
activation in the development of hemodynamic tolerance to
nitroglycerin.
Methods
Study patients. Thirteen men (aged 43 to 72 years, mean
61) were studied. All had severe chronic congestive heart
failure (New York Heart Association functional class IV)
caused by ischemic heart disease. No patient had had an
acute myocardial infarction or unstable angina in the previ-
0735-1097/90/$3.50
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ous 6 months. The patients were admitted and stabilized in
hospital for a minimum of 5 days on a 2g sodium diet and 1.5
liters fluid restriction per day. All patients were at bed rest.
All vasodilators were discontinued a minimum of 5 days
before the study. and patients were maintained on digoxin
and diuretic drugs. Once considered maximally controlled
with <0.5 kg weight change over 3 consecutive days. they
were transferred to the coronary care unit. Patients were
maintained on a 2g sodium diet and 1.5 liters fluid restriction
and were weighed daily throughout the study. The 1.5 liter
fluid restriction included both oral and intravenous liquids
such that when intravenous liquids were given. oral intake
was reduced correspondingly. Written informed consent was
obtained from every patient. All study procedures were
approved by the Ethics Committee of H6pital du Sacre-
Coeur de Montreal on March 21. 1988.
Preinfusion measurements. The evening before the study
(23). a 7F triple lumen. flow-directed. balloon-tipped ther-
modilution catheter (Edwards Laboratories) was inserted
transcutaneously through the right internal jugular vein by
the Seldinger technique and advanced to a pulmonary wedge
position according to pressure tracings. Pulmonary artery.
right atrial and pulmonary capillary wedge pressures were
monitored using a Gould-Statham P2311d transducer and
were recorded on an Electronics for Medicine VR-6 photo-
graphic recorder. Cardiac output was measured in triplicate
by means of the computerized thermodilution technique by
injecting 10 ml iced 5% dextrose in water. Systemic arterial
blood pressure was measured through a radial cannula. All
derived hemodynamic variables were calculated as previ-
ously described (24).
The next morning. while the patient was still fasting and
before being given any medication. a sample of blood was
drawn. labeled with chromium and reinjected into the patient
to measure red blood cell and intravascular volume. After 30
min of equilibration. baseline hemodynamic measurements
were obtained and blood was drawn from the arterial can-
nula for measurement of red blood cell volume. hematocrit
and hemoglobin. creatinine. blood urea nitrogen and plasma
neurohumoral levels (renin. aldosterone. arginine vasopres-
sin. atrial natriuretic peptide. norepinephrine and epineph-
rine).
Infusion protocol. Patients were then randomly assigned
to receive either nitroglycerin alone or nitroglycerin plus
N-acetylcysteine. When patients were given nitroglycerin
alone. the drug was started at 0.25 ILg/kg body weight per
min (0.8 mg of nitroglycerin/ml 5% dextrose in water) and
increased by 0.25 ILg/kg per min increments every 5 min to a
maximum of 1.5 ILg/kg per min. This target dose is slightly
higher than the average infusion rate used in patients with
rest angina (25.26). In our experience. it is well tolerated and
effective in patients with severe heart failure. The use of a
fixed target dose stems from the fact that in this condition.
blood pressure is often low even before nitroglycerin admin-
istration. Therefore. a decrease in blood pressure as an end
point may not be as useful in monitoring clinical response in
these patients as it is in those with rest angina.
The target dose was reached within the Ist hour in all
patients. When a patient received nitroglycerin and N-ace-
tylcysteine, both infusions were started together. Nitroglyc-
erin infusion was started and increased as just described.
N-acetylcysteine was given in the following manner: 50
mg/kg (in 100 m15% dextrose in water) in the first 30 min. 25
mg/kg per h (total of 200 ml 5% dextrose in water) for the
next 2 h, then 100 mg/kg (in a total of 500 m15% dextrose in
water) over the next 21.5 h. Maximal nitrate infusion rate
could not be obtained until the 6th hour of infusion in five
patients receiving N-acetylcysteine because of hypotension
(systolic pressure <90 mm Hg). The 800 ml water given with
the N-acetylcysteine was considered when the 1.5 liters/day
fluid restriction was calculated.
Hemodynamic variables were measured and blood sam-
ples were drawn for hematocrit. hemoglobin. creatinine and
blood urea nitrogen after I. 6 and 24 h of nitroglycerin
infusion. Plasma neurohumoral levels were only measured I
and 6 h after the beginning of the infusion. Once the 24 h
infusion was complete. patients treated with nitroglycerin
alone received an increased rate of infusion to 7.0 ILg/kg per
h for 30 min and hemodynamic measurements were re-
peated. Patients treated with nitroglycerin plus N-acetylcys-
teine received a bolus injection of 50 mg/kg (in 100 ml 5%
dextrose in water) of N-acetylcysteine given over 30 min and
hemodynamic measurements were repeated. All infusions
were then stopped.
Twenty-four hours later. all patients underwent the same
protocol except for two differences: I) patients who received
only nitroglycerin received nitroglycerin plus N-acetylcys-
teine and vice versa. and 2) no neurohumoral samples were
drawn during the second infusion.
Side effects. Two of the 13 patients did not complete the
study. One patient had an allergic reaction to N-
acetylcysteine and received two infusions of nitroglycerin
alone. Asecond patient developed signs of thrombosis of the
right subclavian vein during the second infusion. The first
infusion with nitroglycerin alone was completed without
problems. but the second infusion with nitroglycerin plus
N-acetylcysteine was not completed. For these reasons.
there were 14 infusions of nitroglycerin alone and II infu-
sions of nitroglycerin plus N-acetylcysteine.
Total blood volume determination. Before the first infu-
sion. total red blood cell volume and intravascular volume
were determined by the use of the dilution principle. A 12 ml
sample of blood was drawn from the arterial cannula and
added to 2 ml A-C-D solution (Frosst) (to ml solution
contains 132 mg dextrose. 250 mg sodium citrate. 80 mg
citric acid and 10 ml distilled water) in a sterile vial to which
1.85 mBq chromium-51 was added. The vial was gently
shaken and incubated in a water bath at 37°C for 20 min. The
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vial was then placed at room temperature and 50 mg ascorbic
acid was added to stop the labeling process. Ten minutes
later, 5 ml labeled blood was reinjected into the patient
through the proximal port of the Swan-Ganz catheter. A
period of 30 min was allowed to assure homogeneous distri-
bution of the labeled erythrocytes in the vascular space,
after which a blood sample was taken from the arterial
cannula. The blood hematocrit level was determined for the
injection mixture and for the patient's blood. Aliquots of 2
mJ blood and 2 ml plasma obtained from the injection
mixture and from the patient were then counted. Back-
ground activity on 2 ml aliquots of blood and of plasma taken
before red cell labeling was also determined and subtracted
from the appropriate samples to obtain the net number of
counts.
The total red blood cell volume could then be determined
by the following formula:
5[STD - PLIO - HTI)]
TGV = .
PT - PL~(1 - HT~)
where TGV = total red blood cell (globular) volume (mil,
STD = counts/min in 2 ml blood from the injection mixture
(standard), PT = net counts/min in 2 ml blood from the
patient, PL. = counts/min in 2 ml plasma from the injection
mixture, PL~ = net counts/min in 2 ml plasma from the
patient, HTI = injection mixture hematocrit and HT~
patient hematocrit.
Total blood volume (rBV) was calculated as:
TGV I
TBV = - x --.
HT~ 0.915
where 0.915 represents the correction factor to convert
venous hematocrit into total body hematocrit. When arterial
samples were drawn, this correction factor was omitted. For
each patient, it was assumed that the total red blood cell
(globular) volume remained constant throughout the study
and consequently served as a standard to measure the
intravascular volume changes during the nitrate infusions.
Vascular volume determinations could not be obtained in
three patients because they had been exposed to radioactive
diagnostic products in the month preceding the study.
Control patients to validate the technique. Seven pa-
tients with severe congestive heart failure (New York Heart
Association class III or IV) had blood volume determined as
inpatients (n = 3) or as outpatients (n = 4). These control
patients continued their regular medications without any
modification and had a strict fluid restriction of 1.5 liters/day
(including the intravenous solution given during the Ist day
of the study). Red blood cell labeling and blood sampling for
hematocrit determination were done over 72 h at the same
intervals as for the study patients. The hospitalized control
patients remained at bed rest for the duration of the study.
whereas the outpatient control subjects were admitted to the
research outpatient clinic on 3 consecutive mornings and
remained at bed rest at least I h before blood sampling and
throughout the day. On the 1st day of the study, an infusion
of 5% dextrose in water was given at a rate of 40 ml/h for 8 h
to facilitate the labeling process and blood sampling.
Estimated mean total body radiation dose for blood
volume determination in each patient was 20.8 ± 18.6
millirads.
Other methods and techniques, Arginine vasopressin,
plasma renin activity and aldosterone were measured ac-
cording to methods previously developed and reported by
our laboratory (24). Atrial natriuretic peptide was measured
by radioimmunoassay according to the technique of Wilson
et al. (27). Arterial norepinephrine and epinephrine levels
were measured according to the radioenzymatic assay of
Peuler and Johnson (28). The normal values in our labora-
tory are as follows: plasma renin activity <2.5 ng/ml per h
for a normal sodium diet, plasma aldosterone ~25 ng/dl for a
normal sodium diet, plasma vasopressin 0.5 pg/ml to 2.5
pg/ml for a plasma sodium level between 135 and 145
mEq/liter. Normal values for atrial natriuretic peptide are
<30 pg/ml. Normal values for arterial norepinephrine are
170 ± 40 pg/ml and for epinephrine 35 ± 8 pg/ml. Hemodi-
lution was measured as the percent change in hematocrit
compared with baseline values.
Statistical analysis. Patients were divided in two groups
according to whether they received nitroglycerin alone or
nitroglycerin plus N-acetylcysteine. For each group, sequen-
tial measurements of hemodynamic variables, body weight,
neurohormones, hematocrit and total blood volume were
analyzed by a repeated measures analysis of variance fol-
lowed, when a significant change was found, by the multiple
comparison test of Newman-Keuls. Total blood volume
measurements in the control group were analyzed by a
repeated measures analysis of variance, followed by Oun-
net's test. Total blood volume variation for the entire study
group as a function of time was fitted by a rectangular
hyperbola with the use of a simplex algorithm method (29).
Statistical significance was accepted at p < 0.05. Unless
otherwise stated. all values are mean values ± SE.
Results
The study patients had severe congestive heart failure
and significant neurohumoral activation (Fig. I and 2). These
patients also had mild renal failure (serum creatinine 1.47 ±
0.32 mg/dl and blood urea nitrogen 33 ± 2 mg/dl [mean ±
SO]).
Hemodynamic and neurohumoral measurements. The
overall hemodynamic effects of the 24 h nitroglycerin infu-
sions were similar whether nitroglycerin was given alone or
in combination with N-acetylcysteine. The same partial
tolerance to nitroglycerin occurred with both treatment
regimens. The only difference was that it took 6 h to reach
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Figure 1. Hemodynamic changes caused by a
24 h infusion of nitroglycerin (filled circles) with
and without N-acetylcysteine (open circles). Val-
ues are indicated at control (C) and at I, 6 and
24 h of infusion. The arrow at 24 h indicates
values after increasing the rate of nitroglycerin
infusion. N-acetylcysteine did not significantly
alter the hemodynamic effects of nitroglycerin.
Increasing the nitroglycerin infusion rate further
decreased arterial and ventricular filling pres-
sures. A bolus injection of N-acetylcysteine at
the end of the infusion had no effect. For clarity,
only the largest standard error of the mean for
each group is indicated. *p < 0.05 and **p < 0.01
versus control and tp < 0.05 and ttp < 0.01
versus I h. HR = heart rate; MAP = mean
arterial pressure; PAP = mean pulmonary artery
pressure; PCWP = pulmonary capillary wedge
pressure; RAP = right atrial pressure; SVI =
stroke volume index; SVR = systemic vascular
resistance; SWI = stroke work index.
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maximal nitroglycerin infusion rates in 5 of II patients
receiving N-acetylcysteine because of hypotension. whereas
all patients receiving only nitroglycerin reached maximal
infusion rates after I h. After I h of infusion, mean arterial,
pulmonary artery, pulmonary capillary wedge and right
atrial pressures and systemic vascular resistance all de-
creased significantly, whereas there was no significant
change in heart rate, stroke volume or stroke work index
(Fig. I), although stroke volume and stroke work index
tended to increase in both groups. These decreases in
arterial and ventricular filling pressures were accompanied
by an increase in arterial epinephrine and plasma renin
activity and a decrease in atrial natriuretic peptide (Fig. 2).
There was no change in arterial norepinephrine, aldosterone
or arginine vasopressin levels.
After 6 h ofcontinuous infusion, no further hemodynamic
changes occurred, except that mean arterial pressure tended
to increase and this increase was significant in patients
receiving N-acetylcysteine (Fig. I). This increase might have
been greater had a maximal nitroglycerin dose been achieved
in all of these patients by I h of infusion. By 6 h of infusion,
mean arterial. pulmonary artery, right atrial and pulmonary
capillary wedge pressures and systemic vascular resistance
all remained lower than control values (Fig. I). Again, there
was no change in heart rate, stroke work or stroke volume
index. although stroke volume and stroke work index both
still tended to be higher than baseline values. By 6 h of
continuous infusion, arterial epinephrine levels had returned
to baseline values, possibly because of less pronounced
hypotension; however. plasma renin activity still remained
elevated and atrial natriuretic peptide continued to be de·
creased (Fig. 2). There was no change in the levels of the
other neurohormones (norepinephrine, aldosterone and argi-
nine vasopressin).
After 24 II of continuolls infusion, mean pulmonary ar·
tery, pulmonary capillary wedge and right atrial pressures
were all still decreased compared with baseline measure-
ments (Fig. I). However, except for atrial pressure in the
N-acetylcysteine group, all of these variables had increased
compared with values after I h of infusion. By 24 h of
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Figure 2. Neurohumoral changes during
the first 6 h of nitroglycerin infusion.
Arterial epinephrine increased after I h
of infusion. then returned to the baseline
value. Plasma renin activity (PRA) in-
creased and atrial natriuretic peptide
(ANP) decreased throughout the first 6 h
of the infusion. Filled circles = patients
with nitroglycerin alone (n =7) and open
circles = patients with nitroglycerin plus
N-acetylcysteine (n = 6); p values are
indicated when significant. AVP = argi-
nine vasopressin.
continuous infusion, mean arterial pressure had returned to
baseline values in both groups. Although stroke work index
and stroke volume index increased and systemic vascular
resistance decreased similarly in both groups. these changes
were significantly different from baseline values only in the
group taking nitroglycerin alone.
Increasing the nitroglycerin infusion rate from 1.5 to 7
p.g/kg per min after 24 h in the group receiving only nitroglyc-
erin caused a further decrease in mean pulmonary artery,
pulmonary capillary wedge and right atrial pressures (Fig. I). It
also caused a decrease in mean arterial pressure but did not
significantly alter other hemodynamic variables. Increasing the
infusion rate of N-acetylcysteine (50 mg/kg bolus injection) did
not significantly alter hemodynamic values.
Blood volume measurements. Throughout the 24 h infu-
sion. hematocrit decreased and total blood volume increased
(Fig. 3). These changes occurred despite fluid restriction and
there was no change in mean body weight (day O. 65.2 ± 8.7;
day I, 65.5 ± 8.5; day 2, 65.2 ± 8.6; and day 3. 65.4 ± 8.8
kg). By I h of continuous infusion. hematocrit decreased and
total blood volume increased similarly in both groups. indi-
cating that the fluid injected with the N-acetylcysteine had
no bearing on these results.
Total blood volume continued to increase between I Gnd
24 h of infusion in both groups. Both groups had a similar
degree of hemodilution after 24 h of infusion (9.1 ± 4.3% for
nitroglycerin alone and 8.7 ± 4.1% for nitroglycerin plus
N-acetylcysteine). When both groups are considered to-
gether. this hemodilution resulted in an increase in intravas-
cular volume of 745 ± 382 ml. When the percent changes in
total blood volume of the individual patients are plotted as a
function of time. data points are best fitted by a rectangular
hyperbola (standard deviation of the equation 1.20 x 10- 1•
sum of squared residuals 2.28 x 10- 1) (Fig. 4):
0.141T
Change in total blood volume = ,
T + 0.550 h
where T represents the time in hours. The coefficient in the
numerator represents the maximal asymptotic value for the
change in blood volume 04.1%). The second term in the
denominator (0.550 h) represents the time at which half of
the asymptote has been reached. There was no change in
blood volume in our control patients (Fig. 5).
Discussion
Hemodynamic tolerance to nitroglycerin appears to be
multifactorial. This study suggests that the development of
hemodynamic tolerance to nitroglycerin in patients with
congestive heart failure is multifactorial. As previously
reported (I). a major mechanism of tolerance appears to be
928 DUPUIS ET AL.
NITRATE TOLERANCE IN HEART FAILURE
JACC Vol. 16. No.4
October 1990:923-31
•e •
ttl •• •• • I• •I I •- _. 0: • _ 0 0 0 0 0 0 0 0 0 .eoe
0.46
0.45
0.44
I- 0.43a:
(J 0.42
0
I- 0.41
C(
::E 0.40
W
1: 0.39
0.38 •• **
0.37
0.36
1.32
1.26
1.20
c
~ 1.14
>
1.08
1.02
0.96
·5 o 5 10 15 20
e
e
I
25
tt
time (hours)
Figure 3. Changes in hematocrit and blood volume during nitroglyc-
erin infusion. Hematocrit decreased and blood volume increased
similarly in both groups. For clarity only the largest standard error
of the mean for each group is illustrated. *p < 0.05 and **p <
0.01 versus control and tp < 0.05 and ttp < 0.01 versus I h. Open
circles = patients who received only nitroglycerin (n = 11) and filled
circles = patients who received nitroglycerin plus N-acetyJcysteine
(n = 8).
a loss of pharmacologic effect of the drug on vascular smooth
muscle. However. in this study, the simultaneous infusion of
N-acetylcysteine did not prevent the development of the
partial hemodynamic tolerance that was observed with ni-
troglycerin alone. A second mechanism, a large fluid shift
from the extravascular to the intravascular space, appears to
be involved, especially during the 1st hour of infusion when
this fluid shift is greatest. A third mechanism, neurohumoral
activation, also seems to contribute to the development of
tolerance to nitroglycerin.
Comparison with previous studies involving N-acetylcys-
teine. The most probable cause for the differences in results
between this study and previous investigations (5,14) is the
dosages of N-acetylcysteine and nitroglycerin used. N-
acetylcysteine has been shown to potentiate the effects of
nitroglycerin and increase arteriovenous nitroglycerin ex-
traction (3(}-32). This reaction appears to be dose dependent.
to occur largely in plasma and to result in nonspecific
vasodilation whether or not nitrate tolerance exists (15).
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Figure 5. Blood volume measurements (±SEM) in seven control
patients with stable heart failure over a 3 day period. There was no
increase in blood volume.
Both Packer et al. (5) and May et al. (14) used large acute
doses of N-acetylcysteine (200 and 100 mg/kg) and large
doses of nitroglycerin (6.4 j.Lg/kg per min and 45 j.Lg/min
intravenously. respectively. plus large intracoronary doses
[10 to 100 j.Lg)) and it may be that such large circulating levels
of these medications resulted in the extracellular conversion
of organic nitrates to an active compound (15,33-35). The
need for a combination of high circulating nitroglycerin and
N-acetylcysteine levels for "apparent nitrate tolerance re-
versal" would certainly explain why Packer et al. (5) had
such a brief «90 min) beneficial effect with N-acetylcys-
teine.
Thus. the effects of N-acetylcysteine in their study may
have been the result of an extracellular reaction between
high circulating doses of nitroglycerin and N-acetylcysteine
rather than intracellular smooth muscle cell sulfhydryl group
repletion. This extracellular activation of nitrates to an
Figure 4. Assessment of time course and maximal variation in the
total blood volume of patients receiving intravenous nitroglycerin.
Data points were best fitted by a rectangular hyperbola; standard
deviation = 1.20 x 10- 1; sum of squared residuals = 2.28 x 10- 1•
The maximal asymptotic value for the variation of blood volume is
14.1%. VIVo represents the ratio of individual blood volumes over
the baseline blood volumes. The dotted line represents a ratio of I.
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active compound appears to occur with nitroglycerin but not
with isosorbide dinitrate (33). This specificity may explain
why Parker et al. (17) were unable to reverse tolerance to the
beneficial effects of isosorbide dinitrate on exercise capacity
in patients with angina. Alternatively, the dose of isosorbide
dinitrate (30 mg) or of N-acetylcysteine (100 mg/kg) may
have been too small to obtain reversal of tolerance.
It is possible that the dose ofN-acetylcysteine used in this
study was inadequate to replete intracellular sulfhydryl
groups. However, if one considers the decrease in volume of
distribution and hepatic clearance that occurs in heart failure
(36,37), the dose used in this study was likely superior to that
found effective in treating acetaminophen intoxication
(38,39). Therefore, adequate circulating levels of N-
acetylcysteine to provide sulfhydryl groups were likely
present. In addition, the doses used in this study were
equivalent if not larger than the doses used to decrease the
incidence of myocardial infarction in patients with unstable
angina (40). Finally, it is unlikely that an inadequate number
of sulfhydryl group donors was the only reason for the lack
of effect of N-acetylcysteine in our study because the bolus
injection of N-acetylcysteine given at the end of the study
had no effect.
One obvious difference between this study and previous
investigations (5,14) is the length of time the N-acetylcys-
teine had been given before taking hemodynamic measure-
ments. In our study, N-acetylcysteine was infused for 24 h to
prevent tolerance, whereas in the previous investigations,
N-acetylcysteine was given acutely to reverse tolerance.
Although unlikely because of its continued efficacy in treat-
ing acetaminophen overdose, it is possible that a certain
tolerance to the beneficial effects of N-acetylcysteine occurs
with time and that a second mechanism of nitrate tolerance
occurs, perhaps a change in enantioselectivity (16).
The degree of tolerance achieved in this study was less
than that described in previous studies (5,6). This difference
could be related to the shorter period of infusion (24 versus
48 h) and may at least partially explain why N-acetylcysteine
did not prevent the development of tolerance. The contribu-
tion of pharmacologic tolerance during this relatively short
period of infusion may have been insufficient to document a
significant effect of N-acetylcysteine. Had the duration of
infusion been longer and tolerance more complete, N-
acetylcysteine might have been more effective. For all
practical purposes, however, N-acetylcysteine does not ap-
pear to be a clinically useful agent in preventing early
tolerance to nitroglycerin.
Role of fluid shift. Our results suggest that a second
mechanism, a fluid shift from the extravascular to intravas-
cular space, may playa role in the development of nitrate
tolerance. This fluid shift would result in an increased
intravascular volume, which would counterbalance the va-
sodilating effects of nitroglycerin. An increase in intravascu-
lar volume has already been shown to be the major cause of
tolerance to nearly all vasodilators used to treat hyperten-
sion (20,21) and there is no reason to believe that an increase
in intravascular volume as large as the one documented in
this study did not influence our hemodynamic findings.
The large increase in intravascular volume occurred despite
strict fluid restriction (1.5 liters/day) before and during the
study. The 1.5 liter fluid restriction included both oral and
intravenous liquids, when extra intravenous liquids were given,
oral intake was reduced correspondingly. It is unlikely that
such an increase in intravascular volume was the result of
intravenous fluid administration itself because the thermodilu-
tion catheter was inserted and intravenous infusions were
started the evening before beginning the study. Also, between
nitroglycerin infusions, hematocrit and blood volumes returned
toward baseline values despite continued intravenous fluid
administration. No change in body weight occurred throughout
the study and the major portion of the increase in intravascular
volume occurred so quickly that a shift of fluid from the
extravascular to intravascular space is the most likely expla-
nation for our findings.
The reason for this fluid shift remains speculative, but it
may simply be the result of modification of Starling forces in
the capillary bed caused by preferential vasodilation of veins
and venules as opposed to arteries and arterioles (3,4).
Intravascular hydrostatic forces favoring extravasation of
fluid from the capillaries to the extravascular space would be
decreased, thus favoring an increase in intravascular vol-
ume. The end result would be similar to what happens when
a patient with heart failure moves from the standing to the
supine position. Because fluid balance and body weight
remained stable throughout the study, the use of fluid
loading or diuretic drugs to further study the effects of fluid
shifts on nitrate tolerance would have been difficult to
interpret because these interventions would have resulted in
an increase or decrease in total body fluid and by themselves
would have modified all hemodynamic variables.
The fluid shift occurred mostly during the 1st h of the
infusion. This may be one reason why increasing perfusion
rates of nitroglycerin over 1 or 2 h is better tolerated than
starting the same dose suddenly. Intravascular volume also
continued to increase, but to a lesser extent, between h I and
h 24 of nitroglycerin infusion. A fluid shift may therefore
have played a role in the development of the partial tolerance
to nitroglycerin that was observed in this study, and may
help explain why N-acetylcysteine was unsuccessful in
preventing it.
Role of neurohormones. During the nitroglycerin infu-
sion, there was an increase in arterial epinephrine and
plasma renin activity and a decrease in atrial natriuretic
peptide levels. This decrease in atrial natriuretic peptide
levels, which occurred despite volume expansion, may be
explained by the lower atrial pressures recorded throughout
the infusion. Neurohumoral activation may have been useful
in maintaining arterial pressure during the first hours of
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infusion. However, because epinephrine decreased to base-
line values between h I and h 6 of the infusion and other
neurohormones did not change during this period, it is
unlikely that neurohumoral activation caused the observed
loss of effect of nitroglycerin. What long-term effects an
increase in plasma renin activity and decrease in atrial
natriuretic peptide would have in these patients are uncer-
tain, but there is good reason to believe that it would lead to
volume expansion, an increase in systemic vascular resis-
tance and a loss of the initial beneficial effects of nitroglyc-
erin. In a previous study (5), intravenous nitroglycerin was
found to cause a sustained (48 h) increase in plasma renin
activity and an increase in body weight. However, two other
studies (6,18) did not report such findings, and the role of
long-term reflex neurohumoral activation in the development
of tolerance remains to be determined.
This study may have underestimated the role (~f ncuro-
humoral changes in the development of nitrof<lycerin toler-
ance for two reasons. I) It was done with the patient in the
supine position and postural hemodynamic and neuro-
humoral changes caused by nitroglycerin were not assessed.
Measurements in patients in the upright position (41) or
during exercise (42) may have brought out differences in
neurohumoral activation not seen at rest. 2) As a result of
strict control of sodium and water intake during this study,
the tendency toward sodium and water retention was mini-
mized, such that a neurohumorally mediated tendency
toward volume expansion may have been missed. Longer
follow-up study would have been necessary to fully appre-
ciate the contribution of reflex neurohumoral activation to
long-term nitrate tolerance.
Conclusions. This study suggests that the development of
tolerance to hitroglycerin is multifactorial. A loss of phar-
macologic effect of nitroglycerin on smooth muscle has been
well described, but in the present study, the simultaneous
infusion of N-acetylcysteine in doses shown effective in
treating acetaminophen intoxication did not prevent the
development of the partial hemodynamic tolerance that was
observed with nitroglycerin alone. These results do not
support a practical role for N-acetylcysteine in preventing
early tolerance to nitrates in congestive heart failure. A
second mechanism, a fluid shift from the extravascular to the
intravascular space, seems to contribute to hemodynamic
tolerance to nitroglycerin. especially during the Ist hour of
infusion. A third mechanism. neurohumoral activation, may
also be involved in early tolerance to nitroglycerin. Because
of the nature of this study. however. the role of neurohor-
mones in the development of nitroglycerin tolerance may
have been underestimated.
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